<?xml version='1.0' encoding='utf-8'?>
<document id="16370963"><sentence text="Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions."><entity charOffset="7-14" id="DDI-PubMed.16370963.s1.e0" text="fibrate" /></sentence><sentence text="Patients with the metabolic syndrome and/or Type 2 diabetes mellitus continue to have a high risk of coronary heart disease (CHD) and progression of atherosclerotic lesions despite aggressive statin therapy" /><sentence text=" Although the National Cholesterol Education Programme Adult Treatment Panel III guidelines recommend the use of fibrates in combination with statins in patients at very high risk of CHD (e"><entity charOffset="23-34" id="DDI-PubMed.16370963.s3.e0" text="Cholesterol" /><entity charOffset="183-186" id="DDI-PubMed.16370963.s3.e1" text="CHD" /><pair ddi="false" e1="DDI-PubMed.16370963.s3.e0" e2="DDI-PubMed.16370963.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16370963.s3.e0" e2="DDI-PubMed.16370963.s3.e1" /></sentence><sentence text="g" /><sentence text=", patients at the low-density lipoprotein cholesterol target with high triglycerides and low high-density lipoprotein cholesterol, many physicians remain reluctant to use these combinations due to concerns of myotoxicity"><entity charOffset="42-53" id="DDI-PubMed.16370963.s5.e0" text="cholesterol" /><entity charOffset="71-84" id="DDI-PubMed.16370963.s5.e1" text="triglycerides" /><entity charOffset="118-129" id="DDI-PubMed.16370963.s5.e2" text="cholesterol" /><pair ddi="false" e1="DDI-PubMed.16370963.s5.e0" e2="DDI-PubMed.16370963.s5.e0" /><pair ddi="false" e1="DDI-PubMed.16370963.s5.e0" e2="DDI-PubMed.16370963.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16370963.s5.e0" e2="DDI-PubMed.16370963.s5.e2" /><pair ddi="false" e1="DDI-PubMed.16370963.s5.e1" e2="DDI-PubMed.16370963.s5.e1" /><pair ddi="false" e1="DDI-PubMed.16370963.s5.e1" e2="DDI-PubMed.16370963.s5.e2" /></sentence><sentence text=" Recently conducted metabolic and pharmacokinetic drug-drug interaction studies using gemfibrozil or fenofibrate in combination with five commonly used statins demonstrated a widely different drug interaction potential for these two fibrates"><entity charOffset="86-97" id="DDI-PubMed.16370963.s6.e0" text="gemfibrozil" /><entity charOffset="101-112" id="DDI-PubMed.16370963.s6.e1" text="fenofibrate" /><pair ddi="false" e1="DDI-PubMed.16370963.s6.e0" e2="DDI-PubMed.16370963.s6.e0" /><pair ddi="false" e1="DDI-PubMed.16370963.s6.e0" e2="DDI-PubMed.16370963.s6.e1" /></sentence><sentence text=" Gemfibrozil causes a 2- to 6-fold increase in statin area under the curve and increases the exposure to many recently approved drugs for the treatment of diabetes"><entity charOffset="1-12" id="DDI-PubMed.16370963.s7.e0" text="Gemfibrozil" /></sentence><sentence text=" Alternatively, fenofibrate does not adversely affect either the metabolism or pharmacokinetics of the statins studied"><entity charOffset="16-27" id="DDI-PubMed.16370963.s8.e0" text="fenofibrate" /></sentence><sentence text=" These pharmacokinetic differences appear to translate into less potential for interactions with fenofibrate/statin combination therapy compared to gemfibrozil/statin co-administration"><entity charOffset="97-108" id="DDI-PubMed.16370963.s9.e0" text="fenofibrate" /><entity charOffset="148-159" id="DDI-PubMed.16370963.s9.e1" text="gemfibrozil" /><pair ddi="false" e1="DDI-PubMed.16370963.s9.e0" e2="DDI-PubMed.16370963.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16370963.s9.e0" e2="DDI-PubMed.16370963.s9.e1" /></sentence><sentence text=" The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in 10,000 patients with Type 2 diabetes mellitus is testing the efficacy and safety of fenofibrate/statin combination"><entity charOffset="157-168" id="DDI-PubMed.16370963.s10.e0" text="fenofibrate" /></sentence><sentence text="" /></document>